Strategic Clinical Opportunities Aethlon’s Hemopurifier carries FDA Breakthrough Device designation for cancer and an open IDE for life-threatening viral infections, highlighting high-potential partnerships with oncology and infectious disease care teams seeking advanced therapeutic options.

Clinical Expansion Recent trial updates show Cohort 3 expansion for oncology studies and ongoing development, signaling opportunities to engage oncology clinical trial networks, KOLs, and patient advocacy groups to support trial enrollment and site collaboration.

Strategic Partnerships Active engagement with Maxim Group LLC as exclusive financial advisor indicates readiness for strategic opportunities such as license deals, co-development, or equity partnerships to accelerate commercialization and clinical adoption.

Healthcare Tech Stack Company leverages cloud and data tools (AWS, Cloudflare, Piwik PRO, Microsoft 365) suggesting readiness for data-driven outcomes, remote monitoring, and digital integration with hospital information systems to support device efficacy tracking and post-market surveillance.

Market Positioning Revenue scale ($25–50M) and a focused team (11–50 employees) imply potential value in mid-market hospital networks and specialty cancer centers, where targeted outreach and case studies could demonstrate Hemopurifier’s impact on immune modulation and exosome-related cancer dynamics.